About OncoCyte Corp (NYSEAMERICAN:OCX)
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NYSEAMERICAN:OCX
- Previous Symbol: AMEX:OCX
- CUSIP: N/A
- Web: www.oncocyte.com
- Trailing EPS: ($0.50)
- Return on Equity: -211.74%
- Return on Assets: -111.72%
- Outstanding Shares: 31,430,000
Frequently Asked Questions for OncoCyte Corp (NYSEAMERICAN:OCX)
What is OncoCyte Corp's stock symbol?
OncoCyte Corp trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte Corp's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) issued its earnings results on Monday, February, 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11). View OncoCyte Corp's Earnings History.
Where is OncoCyte Corp's stock going? Where will OncoCyte Corp's stock price be in 2017?
2 brokerages have issued twelve-month price objectives for OncoCyte Corp's stock. Their forecasts range from $7.75 to $7.75. On average, they expect OncoCyte Corp's stock price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte Corp.
Who are some of OncoCyte Corp's key competitors?
Some companies that are related to OncoCyte Corp include Mersana Therapeutics (MRSN), MannKind Corporation (MNKD), AVEO Pharmaceuticals (AVEO), NuCana PLC Sponsored ADR (NCNA), Stemline Therapeutics (STML), Calithera Biosciences (CALA), NantKwest (NK), ObsEva SA (OBSV), Mast Therapeutics (SVRA), Biotie Therapies Corp (BITI), Bellicum Pharmaceuticals (BLCM), BioTime (BTX), Ra Pharmctl (RARX), BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Geron Corporation (GERN), Edge Therapeutics (EDGE) and Alcobra (ADHD).
Who owns OncoCyte Corp stock?
Who bought OncoCyte Corp stock? Who is buying OncoCyte Corp stock?
How do I buy OncoCyte Corp stock?
Shares of OncoCyte Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte Corp's stock price today?
One share of OncoCyte Corp stock can currently be purchased for approximately $4.40.
How big of a company is OncoCyte Corp?
OncoCyte Corp has a market capitalization of $184.89 million.
How can I contact OncoCyte Corp?
OncoCyte Corp's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.
MarketBeat Community Rating for OncoCyte Corp (NYSEAMERICAN OCX)MarketBeat's community ratings are surveys of what our community members think about OncoCyte Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for OncoCyte Corp (NYSEAMERICAN:OCX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$7.75|
Consensus Price Target History for OncoCyte Corp (NYSEAMERICAN:OCX)
Analysts' Ratings History for OncoCyte Corp (NYSEAMERICAN:OCX)
(Data available from 11/17/2015 forward)
|5/23/2017||Chardan Capital||Boost Price Target||Buy||$6.50 -> $7.75|
|1/30/2017||Canaccord Genuity||Reiterated Rating||Buy|
|6/7/2016||Benchmark Co.||Boost Price Target||Speculative Buy||$7.50 -> $8.00|
|3/25/2016||Lake Street Capital||Initiated Coverage||Buy||$8.00|
|3/15/2016||Janney Montgomery Scott||Reiterated Rating||Buy||$15.00|
Earnings History and Estimates Chart for OncoCyte Corp (NYSEAMERICAN:OCX)
Earnings History by Quarter for OncoCyte Corp (NYSEAMERICAN OCX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for OncoCyte Corp (NYSEAMERICAN:OCX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for OncoCyte Corp (NYSEAMERICAN:OCX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for OncoCyte Corp (NYSEAMERICAN OCX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for OncoCyte Corp (NYSEAMERICAN:OCX)
Latest Headlines for OncoCyte Corp (NYSEAMERICAN OCX)
OncoCyte Corp (NYSEAMERICAN OCX) Chart for Friday, November, 17, 2017